B · Normal
[Tianyu Co., Ltd.: Wholly-owned subsidiary ibrutinib capsules received drug registration approval] On November 19, Tianyu Co., Ltd. (300702.SZ) announced that the company’s wholly-owned subsidiary Zhejiang Node Pharmaceutical received the “Drug Registration Certificate” for ibrutinib capsules approved and issued by the State Food and Drug Administration. This drug is suitable for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenstrom's macroglobulinemia. According to statistics, the sales of ibrutinib capsules in domestic sample hospitals and urban physical pharmacies in 2025 will be approximately 399 million yuan. As of the announcement date, the company has invested approximately 7.6208 million yuan in research and development of this variety.
A-share announcement express 🕐 2026-11-19 17:49

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet